TP53 and pancreatic adenocarcinoma: Since we and others have shown that, in most cases, TP53 was mutated in pancreatic adenocarcinomas ((Figure 1) [8]), and since, in many cases, the mutated form of p53 had a tendency to accumulate in tumor cells (and, thus, became the attractive target for therapy)—systematically reviewed [43,44,45,46]—we checked for possible correlations between the number of proteins encoded by p53 target genes and survival in the next step.